Stay updated on Adagrasib + BI 1701963 in Cancer Clinical Trial
Sign up to get notified when there's something new on the Adagrasib + BI 1701963 in Cancer Clinical Trial page.

Latest updates to the Adagrasib + BI 1701963 in Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check34 days agoNo Change Detected
- Check41 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference5%
- Check48 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check63 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check70 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.9%
- Check92 days agoChange DetectedThe study has been terminated as of March 8, 2022, due to a change in development strategy, with no results posted, following the completion and submission of results on December 8, 2022.SummaryDifference6%
Stay in the know with updates to Adagrasib + BI 1701963 in Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib + BI 1701963 in Cancer Clinical Trial page.